Navigation Links
New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
Date:4/29/2010

his,'o','ExternalLink');" target='_blank' href="http://www.springer.com/medicine/oncology/journal/10549">http://www.springer.com/medicine/oncology/journal/10549.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA compliant service laboratories. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, Calif
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study
2. Facet Solutions Announces 2 Year Data from US Pilot Study
3. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
4. Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study
5. Study shows potential benefit of dark chocolate for liver disease patients
6. Study shows that size affects structure of hollow nanoparticles
7. ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
8. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
9. New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing
10. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
11. Study quantifies the electron transport effects of placing metal contacts onto graphene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  For about a century, a known ... to utilize and catabolize glucose at a high ... called the ,Warburg phenomenon", that is an increased ... presence, leading to enhanced lactate generation. Even under ... glucose fermentation. A variety of such abnormalities have ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 /PRNewswire/ ... para un nuevo receptor utilizando tecnología de descubrimiento de ... cubierta en el tratamiento de millones de pacientes con ... hoy que ha recibido una patente en Europa titulada ... descubrimiento de Molecular Health de que EPHB4 es un ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research into ... for advancing the creation of safer pharmaceuticals, will be ... , the second-largest private, nonprofit university in California. , ... at the University of Kansas School of Pharmacy who ... 5 p.m. and takes place at National University’s Torrey ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... that the effects of prion disease could be reversed ... findings support developing early treatments that aim to reduce ... with prion disease. Also, they said that their findings ... way: by analyzing their cognitive effects in prion-infected mice. ...
... autopsy data provide the strongest evidence yet that sudden infant ... a concrete biological basis. In the November 1 issue of ... brainstem ?a part of the brain that regulates breathing, blood ... SIDS. , SIDS is the leading cause of death ...
... Jude Children's Research Hospital have demonstrated in a mouse model ... that not only greatly reduces the size of the tumor, ... standard chemotherapy. The treatment also appears to be suitable for ... is simple enough for widespread use even in countries with ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4
... I catalyzes the template-directed polymerization of nucleotides ... DNA Polymerase I possesses a 3?5 exonuclease ... error rate during DNA replication, and also ... the enzyme to replace nucleotides in the ...
... Exonuclease-free Klenow Fragment is a genetically engineered Klenow ... activity has been removed, leaving only the 5 ... activity makes Exo- Klenow Fragment the enzyme of ... probes by the random primed method, and for ...
Request Info...
DNA polymerase I, large fragment...
Biology Products: